6564.TWO Enimmune corporation
- Market cap
- TWD 996M
- P/E
- -
- P/B
- 10.47x
- ROE
- -109.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6564.TWO undervalued?
Graham numberThe Graham number of Enimmune corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enimmune corporation fundamental analysis
No fundamental analysis for Enimmune corporation yet.
Enimmune corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syn…
Full company profileEnimmune corporation financial statements
Enimmune corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.94M | 22.9M | 110M | 188M | 43.5M | 39.9M | 48.2M |
| Gross Profit | 769K | 8.22M | 38.7M | 20.8M | -23.4M | 14.2M | 8.02M |
| Operating Income | -71.9M | -82.7M | -58.7M | -286M | -243M | -151M | -187M |
| EBITDA | -50.7M | -67.3M | -38.4M | -258M | -229M | -156M | -151M |
| Net Income | -56.6M | -74.5M | -47.2M | -248M | -224M | -158M | -164M |
| EPS | -1.28 | -1.39 | -0.78 | -3.88 | -3.40 | -2.20 | -2.28 |
| Balance Sheet | |||||||
| Total Assets | 329M | 658M | 610M | 775M | 605M | 724M | 456M |
| Total Liabilities | 5.71M | 40.4M | 40.0M | 110M | 173M | 244M | 306M |
| Shareholders' Equity | 324M | 617M | 570M | 545M | 322M | 374M | 150M |
| Cash & Short-term Investments | 166M | 429M | 350M | 502M | 380M | 505M | 202M |
| Total Debt | - | 12.0M | 8.08M | 29.7M | 45.7M | 108M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -59.9M | -107M | -71.6M | -201M | -138M | -144M | -143M |
| Capital Expenditure | 0.00 | 4.52M | 3.41M | 347K | 0.00 | 473K | 4.18M |
| Free Cash Flow | -59.9M | -112M | -75.0M | -201M | -138M | -144M | -147M |
| Ratios | |||||||
| ROE | -17.5% | -12.1% | -8.3% | -45.5% | -69.5% | -42.1% | -109.8% |
| ROA | -17.2% | -11.3% | -7.7% | -32.0% | -37.0% | -21.8% | -36.0% |
| Net Profit Margin | -2,913.8% | -325.5% | -43.0% | -131.6% | -514.4% | -394.7% | -341.0% |
| Debt to Equity | - | 0.02x | 0.01x | 0.05x | 0.14x | 0.29x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enimmune corporation dividends
Enimmune corporation has not paid dividends in the last 7 fiscal years.
Who owns Enimmune corporation
Ownership data of Enimmune corporation is not available yet.
Enimmune corporation company profile
- Company name
- Enimmune corporation
- Ticker
- 6564.TWO
- ISIN
- TW0006564008
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 76, Section 2, Taipei, Taiwan, 106485
- Phone
- 886 2 2700 1216
- Website
- enimmune.com.tw
About Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, which is in pre-clinical stage for the treatment of Japanese encephalitis virus; EV71+CA16 bivalent vaccine, which is in research stage for the treatment of hand-foot-mouth disease caused by Coxsackie A virus and enterovirus 71; and Anti-RBD monoclonal antibody, a murine monoclonal antibody for the recognition of receptor binding domain of the SARS-CoV-2 spike protein. The company was founded in 2014 and is based in Taipei, Taiwan. Enimmune Corporation is a subsidiary of Adimmune Corporation.
Enimmune corporation management
2- Zhe Wei ZhangPresident & Manager
- Xiang Rong TangAccounting Supervisor